Avidity
Haley Arellano's work experience starts in 2005 with Cato Research, where they held various positions including Senior Project Coordinator and Regulatory Associate. Haley then joined SynteractHCR in 2009 as a Clinical Research Associate and eventually became a Senior Clinical Research Associate. In 2014, they briefly worked as a Clinical Site Manager at Bristol-Myers Squibb before returning to SynteractHCR as a Clinical Lead. Haley joined Precision For Medicine in 2015 as a Manager of Clinical Operations and progressed to roles such as Senior Manager and Associate Director of Operational Strategy & Feasibility. In 2021, Arellano joined BridgeBio as a Director of Clinical Operations Strategy and is currently working at Avidity Biosciences, Inc. as a Director of Clinical Operations.
Haley Arellano holds a Bachelor of Arts (B.A.) degree in Psychology and Genetics from North Carolina State University. Haley has also obtained a certification as a Certified Mentor from Mentorloop in 2021.
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.